Ben Auspitz
, Managing Partner, Curie.Bio’s Breakout Fund
Ben Auspitz has been in biotechnology for over two decades as an investor, operator, and founder. He started his career in small company biotech moving between operating roles and venture capital.
At Curie.Bio, Ben is responsible for the Breakout Fund. The Breakout Fund has two goals. First, to help scale seed stage companies to move their programs through transformative clinical data. Second, to identify Series A opportunities from outside the company’s own seed ecosystem where Curie’s talented team of drug hunters and developers can give the company an edge in diligence or improve a company’s chances of success.
Before joining Curie.Bio, Ben was a co-founder, founding CEO, and later chairman of IDRx, a company focused on precision oncology. He also co-founded Forge Life Science Partners, a venture capital fund focused on translational stage therapeutic opportunities.
